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Abstract
Uncoupling protein 2 is a member of the mitochondrial anion carrier family that is widely expressed in neurons and the
immune cells of humans. Deletion of Ucp2 gene in mice pre-activates the immune system leading to higher resistance
toward infection and to an increased susceptibility to develop chronic inflammatory diseases as previously exemplified with
the Experimental Autoimmune Encephalomyelitis (EAE), a mouse model for multiple sclerosis. Given that oxidative stress is
enhanced in Ucp22/2 mice and that nitric oxide (NO) also plays a critical function in redox balance and in chronic
inflammation, we generated mice deficient for both Ucp2 and iNos genes and submitted them to EAE. Mice lacking iNos
gene exhibited the highest clinical score (3.4+/20.5 p,0.05). Surprisingly, mice deficient for both genes developed milder
disease with reduced immune cell infiltration, cytokines and ROS production as compared to iNos2/2 mice.
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Introduction
Experimental Autoimmune Encephalomyelitis (EAE) is a
demyelinating disease of the central nervous system (CNS) induced
in susceptible mice strains by active priming with a specific myelin
epitope (MOG35–55) combined with microbial adjuvant. Pathology
of EAE is primarily characterized by a chronic peripheral immune
response in secondary lymphoı ¨d tissue. Consequent infiltration of
lymphocytes and mononuclear cells in the CNS leads to the
autoimmune destruction of the myelin sheath in brain and in the
spinal cord and to neuronal cell death. The clinical expression of
extensive demyelization can be observed as weakness of tail,
moderate forelimb paraplegia and severe paraplegia. Because the
pathological and the clinical aspects of EAE share similarities with
human multiple sclerosis, a disease affecting more than 2.5 million
people worldwide, EAE has been widely used as model to study
genetic and immunological parameters favoring the development
of the disease. Animal models have revealed different immuno-
logical mechanisms of action triggering axonal and neuronal
lesions in spinal cord and in central nervous system. Depending of
the model, auto-antibodies, macrophages or microglia cytotoxic
products, class I MHC restricted cytotoxic cells or class II MHC
restricted Th1 or Th17 cells are involved in the development of
neuroinflammation. All these mechanism are, to some extent,
relevant to human multiple sclerosis diseases showing the
complexity of the disease (for review see [1]). In other hand,
genes controlling energy metabolism and oxidative stress have
been proposed to contribute to MS susceptibility by regulating the
immune system activity and neuronal fitness. The roles of reactive
oxygen species (ROS) in inflammation and in multiple sclerosis
have been exemplified by several groups, suggesting that anti-
oxidant therapies may re-enforce conventional immuno-therapies
developed in the context of auto-immunity [2]. For instance, we
have previously shown that mitochondrial Uncoupling protein 2
(UCP2) has a protective function during EAE [3]. Ucp2 mRNA is
ubiquitous and the protein is readily detectable in tissues such as
the spleen and lungs [4] and in immune cells like macrophages
and T lymphocytes [5]. UCP2 has been shown to regulate ROS
production in immune and in non-immune cells during patholog-
ical conditions such as atherosclerosis [6], type I diabetes [7],
infections [5], cerebral ischemia [8] and EAE [3], thus protecting
the organism from oxidative stress. Human genetic studies have
confirmed these findings since the common G/A polymorphism at
2866 upstream from Ucp2 promoter is linked to atherosclerosis,
diabetes [9] and multiple sclerosis [10]. More recently, we
established a general link between chronic inflammation and
Ucp2 gene by showing that this common polymorphism contrib-
utes to eight other chronic inflammatory diseases, including
rheumatoid arthritis, systemic lupus erythematosus, Wegener’
granulomatosis, and psoriasis [11]. Several groups have suggested
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Kizaki and colleagues showed that UCP2 expression in the
macrophage cell line Raw264 induces a marked reduction of ROS
and iNos gene expression upon lipopolysaccharides (LPS) treat-
ment [12]. Conversely, immune challenge with LPS led to
increased expression of iNOS protein and enhanced NO
production in Ucp2 deficient mice [13]. Emre et al. have proposed
that transient decreases of UCP2 expression at an early stage of
inflammation increases mitochondrial ROS production, which in
turn, activates the mitogen-activated protein kinase pathway thus
leading to iNOS protein expression and enhanced inflammation
[14]. Production of NO is significantly increased in CNS lesions,
MS patients’ blood and urine but also in animals with EAE as
revealed by paramagnetic resonance spectroscopy analysis [15].
NO has long been considered as a potential contributor to EAE
pathogenesis because highly reactive derivatives of NO such as
peroxynitrites induce tissue damage and compromise the blood
brain barrier permeability [16]. However, genetic deletion of iNos
gene was associated with an increased susceptibility of mice to
EAE suggesting an important down-regulatory role of NO on the
immune system both in the periphery and target tissue [17,18].
Indeed, NO can inhibit T lymphocyte proliferation and modulate
the Th1/Th2 cytokines balance by favoring apoptosis or necrosis
of autoreactive Th1 cells [19,20]. Considering the dual effect of
NO in EAE i.e., inhibition of autoreactive T cells and tissue
damaging ability and the protective effect of UCP2 in EAE, we
generated mice deficient for both genes and submitted them to
EAE. Clinical scores and immune parameters demonstrated that
(Ucp2-iNos) deficient mice developed a milder disease associated
with decreased ROS production by macrophages.
Results
Clinical parameters after MOG immunization
As previously reported [3], Ucp2 deficient mice exhibited an
increased score diseases during EAE. However, in this study, score
diseases between Ucp2 deficient mice and control mice were not
significantly different (Fig. 1), while in our previous study a
significant difference was observed all over the induction phase.
This is probably due to the reduced number of mice (18 instead of
40) used in this study (Table 1). Significant differences in disease
severity between iNos deficient mice and the other genotypes were
observed as from day 10. At days 13, 14 and 15, mean clinical
scores were significantly increased in iNos deficient mice as
compared to wild type mice (Fig. 1). Interestingly deletion of
Ucp2 gene in iNos deficient mice significantly delayed the onset of
the disease (p=0.0003) and decreased the severity of the diseases
observed in the iNos deficient mice at day 10, 13 and 14 (Fig. 1,
Table 1). Other clinical parameters, i.e incidence of the disease,
mortality, were not significantly affected (Table 1).
Immune cell infiltration and cytokine production in the
central nervous system upon EAE induction
To evaluate the loss of the BBB integrity and the consequent
infiltration of activated immune cells, mRNA expression levels of
monocytes/macrophages cell marker CD11b (Fig. 2A), and the T
cell markers CD4 (Fig. 2B) and CD8 (Fig. 2C) were assayed by
real-time quantitative RT-PCR. At day 14 after immunization
with the MOG peptide, the iNos deficient mice showed increased
accumulation of CD11b mRNA (p,0.01 versus (Ucp2-iNos)
deficient mice) and of CD4 mRNA (p,=0.05 versus (Ucp2-iNos)
deficient mice). No differences were observed in the accumulation
of CD8 mRNA in the CNS of the different strains. Cytokines
mRNA levels were measured in the inflamed CNS at day 14. The
iNos deficient mice exhibited increased expression of the Th1
cytokines IFNc (Fig. 3A), TNFa (Fig. 3B) and the Th2 cytokine IL-
10 (Fig. 3D) when compared to Ucp2 deficient mice, and (Ucp2-
iNos) deficient mice. Changes in Il-2 levels (Fig. 3D) were not
statistically significant.
Oxidative stress analysis
Reactive Oxygen Species (ROS) are key mediators that can
regulate the intensity of an immune response. In order to assess
the oxidative status of the immune system during EAE, we
measured the ability of peritoneal exudates from MOG immunized
Ucp22/2, iNos2/2 and (Ucp2-iNos) deficient mice to produce
ROS in vitro 10 days after EAE induction (Fig. 4). In vitro
stimulation with PMA generated increased production of ROS by
iNos deficient macrophages compared to Ucp2 and (Ucp2-iNos)
deficient macrophages. Oxidative stress in the brain and in the
spinal cord of mice was also estimated by measuring the levels of
GSH and GSSG. Levels of GSH and of GSSG were not
significantly different between strains (data not shown) but GSSG
content had a tendency to decrease in the CNS of (Ucp2- iNos)
deficient mice (Fig. 5).
Discussion
We have shown that deletion of iNos gene induces a more severe
disease than the deletion of Ucp2 gene. In addition, the
inactivation of both Ucp2 and iNos genes is protective in EAE
progression as demonstrated by delayed onset of the disease,
reduced disease severity, decreased immune cell infiltration and
cytokine production observed in (Ucp2-iNos) deficient mice.
Considering the above results and data available in literature,
we propose the following scenario (Fig. 6). Activated T cells enter
the CNS and they are reactivated by microglia to produce pro-
inflammatory cytokines, IFNc and IL-2. Production of IFNc by T
cells within the CNS activates microglia and resident macrophages
to produce TNFa, NO and ROS. Whereas TNFa allows
recruitment of macrophages in the inflamed CNS, NO readily
diffuses through the mitochondrial outer and inner membranes
where it reversibly inhibits cellular respiration by competing with
oxygen at the level of the cytochrome oxidase [23], thus triggering
a reduced state of the respiratory chain that favors O2.- formation
(Fig. 6). When NO is extensively produced, as is the case in
Ucp22/2 macrophages [13], it may exert cytotoxic effects on
complex I and II of the respiratory chain [24] and thus triggering
ROS production by mitochondria and peroxynitrite formation as
previously observed in atherosclerotic plaque of Ucp22/2 mice
[6]. On the other hand, NO is also known to inhibit the NADPH
oxidase [25], a major player in macrophage ROS production and
an essential gene for the development of EAE since NADPH
oxidase deficient mice are resistant to disease development [26].
NO also acts as a feedback loop to inhibit expansion of
autoreactive T cells and therefore participate to the resolution of
the inflammation (Fig. 6). In iNos deficient mice NO is no longer
produced and this may therefore increase the infiltration and
expansion of autoreactive CD4 cells. Interestingly, our study shows
that inactivation of both Ucp2 and iNos genes leads to a less severe
disease. The decreased ability of (Ucp2-iNos) deficient macrophages
to produce ROS at an early stage of the disease (day 10) may
represent the primary mechanism that confers protection to
double knockout mice.
Despite the fact that UCP2 shares 60% homology with
Uncoupling protein 1, a proton transporter that uncouples ATP
synthesis from mitochondrial respiration in brown adipose tissue,
UCP2 does not seem to ensure such an uncoupling activity in vivo
Ucp2 and iNos Genes in EAE
PLoS ONE | www.plosone.org 2 August 2011 | Volume 6 | Issue 8 | e22841Figure 1. Score disease of mice upon EAE induction. EAE was induced in 7–10 weeks of age mice by subcutaneous injection with 150 mg
MOG35–55 peptide in presence of Freund adjuvant and Pertussis toxin (see Material and Methods). Clinical symptoms were scored as follows: 0,
normal; 1, weak/flaccid tail; 2, waddle; 3, moderate paraparesis; 4, severe paraparesis; 5, tetraparesis; 6, moribund. The mean clinical score was
determined as the average score of all animals for a given genotype at days 10, 13, 14 and 15. Statistical significance was determined by one way
ANOVA and free parametric Kruskal-Wallis test. *, P,0.05; **, P,0.01; ***, P,0.001.
doi:10.1371/journal.pone.0022841.g001
Table 1. Clinical parameters of the mice during Experimental Autoimmune Encephalomyelitis.
N
1 Mean clinical score Mean day of onset Incidence Mortality
(%) (%)
Vogler et al. Day 13 Day 14 Day 15
Ucp2+/+ 25 1.760.2 11.560.8 75
Ucp22/2 40 2.960.2 13.060.6 75
This study Day 13 Day 14 Day 15
Ucp2+/+ 18 1.160.2 1.460.2 1.460.2 11.960.7 90 16.6
Ucp22/2 17 1.460.3 2.360.4 2.560.4 11.860.6 89.4 17.6
iNos2/2 17 2.960.5 3.460.5 3.560.5 10.560.6 94.4 29.4
(Ucp2-iNos)2/2 17 1.460.4 1.760.4 2.460.5 13.560.3 89.5 17.6
1N=number of mice; Data represent means 6 SEM.
doi:10.1371/journal.pone.0022841.t001
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relevant proton transporter as UCP1 is, but rather an anion
transporter. UCP2 protein has recently been proposed as pyruvate
exporter that would transiently change the balance between
glucose and free fatty acid oxidation, thus impacting ROS
production and glucose sensing [31]. This ‘‘pyruvate hypothesis’’
can also impact the redox cytosolic state of the macrophage [32].
For instance, Nuebel et al. reported a decrease of the NADH/
NAD
+ ratio in bone marrow derived macrophages isolated from
Ucp22/2 mice [28]. Moreover the citrate carrier, another
member of the mitochondrial carrier family, has been proposed
to play an anaplerotic function by regulating the cytosolic pool of
NADPH. Indeed, by exporting citrate produced in the mitochon-
drial matrix to the cytosol, the citrate carrier provides substrate for
the cytosolic NADP
+ isocitrate dehydrogenase enzyme, which
generates NADPH [33] that is used by the redox machinery
including the NADPH oxidase, the iNOS synthase and the
glutathione reductase enzymes. Therefore, the cell redox status
results from the level of expression and activity of those enzymes
and from the availability of their substrates (Fig. 6). This ‘‘NADPH
hypothesis’’ need to be further explored in (Ucp2) deficient mice,
because it could explain the decreases in ROS production by
macrophages in (Ucp2-iNOS) deficient mice. Finally, our study
illustrates the interplay between mitochondrial ROS and cytosolic
NO productions in inflammation and highlights the importance of
the mitochondrial metabolism in the redox state of immune cells.
Figure 2. Infiltration of immune cells in the central nervous
system. Both brain and spinal cord from MOG immunized mice of all
genotypes were collected at days 10 (white) and day 14 (grey). Levels of
mRNAs specific for the monocyte cell marker CD11b (A), and for the T
cell markers CD8 (B) and CD4 (C) were assessed by real time
quantitative RT-PCR. The data are expressed as the relative mean 6
SEM of 9–12 mice per genotype using GADPH as the housekeeping
gene. Statistical significance was determined by ANOVA. *, P,0.05;
**, P,0.01; ***, P,0.001.
doi:10.1371/journal.pone.0022841.g002 Figure 3. Relative expression of cytokines mRNA in CNS
homogenates. Fourteen days after EAE induction, brains and spinal
cords were collected and levels of mRNAs were assessed by real time
quantitative PCR as described in Materials and Methods.D a t a
represent mean 6 SEM of 7–12 mice per strain. *, P,0.05; **, P,0.01;
***, P,0.001.
doi:10.1371/journal.pone.0022841.g003
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Animals and induction of EAE
Studies on mice were performed in agreement with the
institutional CNRS guidelines defined by the European Commu-
nity guiding principles and by the French decree Nu87/848 of
October 19, 1987. Authorization to perform animal experiments
was given by the French ministry of Agriculture, fisheries and food
(A92580 issued February 2 1994 and 92–148 issued May 14,
2002). All protocols on mice were declared to the ‘‘Land-
esveterina ¨r- und Lebensmitteluntersuchungsamt Mecklenburg
Vorpommern » gouvernement office and approved under the
permit number No: LVL-MV 310-4/7221.3-1.1-024/2. All
chemicals were obtained from Sigma-Aldrich (Saint Louis, MO).
Double knock out animals were obtained by crossing Ucp22/2
and iNos2/2 deficient mice on the EAE- susceptible C57BL/6
background. The (Ucp22/2) mice have been previously described
[21,22]. The (iNos2/2) mice were obtained from the Jackson
laboratory (Bar Harbor, ME). The F1 generation produced
(Ucp2+/2 iNos+/2) heterozygote mice. The F2 generation
produced (Ucp22/2 iNos+/+) mice, (Ucp2+/+ iNos2/2) and
(Ucp22/2 iNos2/2) mice. All mice were fed with sterile food and
water ad libitum and kept in our animal facility at the Faculte ´d e
Me ´decine Necker in Paris. Inactivation of both genes was
controlled by PCR analysis as previously described [17,21]. EAE
was induced in 7–10 weeks of age mice by subcutaneous injection
with 150 mg of myelin oligodendrocyte glycoprotein (MOG 35–55)
peptide (Genosphere Biotechnologies, Paris, France) dissolved in
50 ml of distilled water and emulsified with an equal volume of
incomplete Freund adjuvant complemented with 4 mg/ml
Mycobacterium tuberculosis (Difco Laboratories, Detroit, MI). Mice
also received an additional peritoneal injection of 400 ng of
Pertussis toxin on day 0 and day 2. Clinical symptoms were scored
as follows: 0, normal; 1, weak/flaccid tail; 2, waddle; 3, moderate
paraparesis; 4, severe paraparesis; 5, tetraparesis; 6, moribund.
The mean clinical score was determined as the average score of all
animals for a given genotype at a given day. Mice showing no
clinical symptoms at all were excluded from the analysis.
ROS production by peritoneal macrophages
Peritoneal macrophages were obtained from diseased animals at
days 10, 14 and 30 after EAE induction. They were subsequently
washed twice in 10 ml ice-cold PBS. Red blood cells were lysed
with a 0.83% NH4CI Tris-Buffered solution. Remaining cells were
then counted and cultured in 96 well plates at a density of 10
5 cells
per well and allowed to adhere for 2 hours at 37uC. Non adherent
cells were eliminated by washing the plates twice with PBS.
Adherent macrophages were stimulated with 500 ng/ml PMA in
100 mL of 1 mg/ml NBT dissolved in RPMI 1640. After one-hour
stimulation, the plates were centrifuged and supernatant was
discarded. The formazan precipitate was washed and dissolved
with an equal volume of DMSO and 2 M KOH solution as
previously described [21]. Absorbance was read at 630 nm.
Real-Time Quantitative RT-PCR
To evaluate cytokine expression and immune cells infiltration,
both spinal cord and brain were collected from diseased mice at
days 10 and 14 after EAE induction. The tissues were individually
grinded in phosphate buffer using a nylon mesh to separate cells.
The suspension was centrifuged at 3000 g for 10 minutes and the
resulting cell pellet was resuspended in 1 ml TRIzol (Invitrogene,
Carlsbad, CA) for RNA isolation according to manufacturer’s
instructions. First strands of cDNA were synthesized from 1 mg
total RNA by using iScript cDNA synthesis kit (Bio-Rad, Hercules,
CA) and then subjected to PCR using specific primers in a Bio-
Rad iCycler iQ real-time detection system. Data were calculated
on the basis of threshold cycle (CT) for the target gene and the
reference gene GADPH according to the following formula: 2
D(CT(GADPH) -C T(Target)). Oligonucleotide sequences used were
IL-4 forward 59-GGT CTC AAC CCC CAG CTA GT-39; IL-4
reverse 59-GCC GAT GAT CTC TCT CAA GTG AT-39; IL10
forward 59-CTG GAC AAC ATA CTG CTA ACC G-39; IL-10
reverse 59-GGG CATC ACT TCT ACC AGG TAA-39; TNFa
forward 59-CCC TCA CAC TCA GAT CAT CTT CT-39; TNFa
reverse 59-GCT ACG ACG TGG GCT ACA G-39; IFN c
forward 59-GAA CTG GCA AAA GGA TGG TGA-39; IFNc
reverse 59-TGT GGG TTG TTG ACC TCA AAC-39; CD4
forward 59-TCA CCT GGA AGT TCT CTG ACC-39; CD4
reverse 59-GGA ATC AAA ACG ATC AAA CTG CG-39; CD8
forward 59-CAT CCT GCT TCT GCT GGC ATT-39; CD8
reverse 59-TGG GCG CTG ATC ATT TGT GAA A-39; CD11b
forward 59- ATG GAC GCT GAT GGC AAT ACC-39; CD11b
reverse 59-TCC CCA TTC ACG TCT CCC A-39; GAPDH
Figure 4. ROS production in macrophages from Ucp22/2,
iNos2/2, and (Ucp2-iNos)2/2 deficient mice. Peritoneal macro-
phages were obtained at day 10 after MOG immunization and
stimulated in vitro with 500 ng/ml phorbol merystil acetate during
1 hour as described in Materials and methods. Data represent mean 6
SEM from 5–13 mice per strain. Student’s t test was performed to
determine the statistical significance of the differences between
Ucp22/2, iNos2/2 and (Ucp2-iNos)2/2 mice. *, P,0.05; **, P,0.01.
doi:10.1371/journal.pone.0022841.g004
Figure 5. Oxidized glutathione in the CNS. Oxidized glutathione
was assayed 14 days after EAE induction, as described in experimental
procedures, in the CNS from Ucp22/2, iNos2/2 and (Ucp2-iNos)2/2
deficient mice. Data represents means 6 SEM of 4–5 mice per
genotype.
doi:10.1371/journal.pone.0022841.g005
Ucp2 and iNos Genes in EAE
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reverse 59- GAC GGA CAC ATT GGG GGT AG-39.
Determination of oxidative stress in CNS
Fresh brain and spinal cord tissues were collected from diseased
animals (day 14) and minced in TES buffer (10 mM Tris, pH 7.5,
1 mM EDTA, 250 mM sucrose). Thirty microliters of the
resulting homogenate was sonified for 30 seconds. Ten microliters
of 10% metaphosphoric acid and 170 ml of 10 mM NaH2PO4,
pH 2.7 were subsequently added to each sample, thoroughly
mixed and allowed to incubate on ice for 10 minutes for
deproteinisation. After incubation, samples were centrifuged for
5 minutes at 15 000 g and supernatant was kept on ice until
analysis. Reduced (GSH) and oxidized glutathione (GSSG) were
simultaneously determined by high-performance liquid chroma-
tography with electrochemical detection. Separation was per-
formed on an Uptisphere column (ODB 25064.6 mm, 5 mm;
Interchim, Montluc ¸on, France) using a mobile phase containing
10 mM NaH2PO4, 1.25% methanol, pH 2.7. Analytical cell
potentials were set at 400 mV for E1 and 900 mV for E2. The
retention times of GSH and GSSG were 5.4 and 12.6 min,
respectively.
Statistical analysis
Evaluation of statistical differences between genotypes was
determined by Anova and Bonferroni’s multiple comparaison test.
In all cases, P,0.05 were considered significant.
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Figure 6. The redox balance in macrophages during inflammation induced by EAE. Once activated, Th1 cells enter the CNS and produce
proinflamatory cytokines (IFNc, Il2) that stimulate resident macrophages. Inflammation is further increased with the autocrine production of TNFa by
macrophages. At the cellular level, ROS production stimulates the expression of proinflammatory genes such as the NO synthase gene. In one hand,
nitric oxide inhibits the respiratory chain (RC), which, in turn, increases the mitochondrial ROS production and consequently oxidative cell damage. In
the other hand, NO prevent Th1 cell expansion and inhibits the NAPH oxidase enzyme, an essential ROS producer that trigger tissue damage and
brain blood barrier destruction. At the molecular level, NADPH plays a pivotal function in the redox balance as substrate of the NADPH oxidase, the
NO sytnhase (iNOS) and the gluthation reductase (GR). In this context, mitochondrial carriers, including UCP2, could modulate the availability of this
substrate. For instance the citrate carrier supplies an additional source of cytosolic NADPH by exporting citrate that is further oxidized into alpha keto
glutarat (a-KG) by the cytosolic isocitrate dehydrogenase (ICDH).
doi:10.1371/journal.pone.0022841.g006
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